On December 2, the Emory University announced the successful completion of the final phase of clinical studies of HIV vaccine, which demonstrated impressive results - 99%efficiency. The drug called Lenacapavir was developed on the basis of MRNA technology, which has already demonstrated its potential for creating vaccines against Covid-19.
- Efficiency: Lenacapavir vaccine has demonstrated the ability to stimulate the immune system to produce specific antibodies that block the spread of HIV virus in the body, with 99%efficiency.
- Clinical research process: tests were conducted on hundreds of volunteers from different age and social groups. The vaccine was tested for the ability to effectively block the virus, even taking into account its genetic variability.
- MRNA technology: The vaccine was developed using mRNA technology, which makes it possible to adapt the drug to various strains of the virus.
- Practicality: Lenacapavir is introduced twice a year, which makes it a convenient alternative for people who cannot take daily oral medicines, as well as for people at risk.
The completion of clinical studies opens the way to further approval by the regulatory organs, which can be an important step in combating one of the greatest health threats - HIV. According to WHO data, more than 38 million people around the world live with this diagnosis.
